29 November 2020 - As the initial rollout starts, it’s time to start planning a registry to monitor health outcomes.

The FDA may approve a COVID-19 vaccine for emergency use within the next few weeks. Within days of that green light, millions of doses will start making their way to patients. The distribution and administration will be logistically complex and difficult. 

And the study of a vaccine’s safety and efficacy doesn’t end with FDA approval. Researchers will be gathering evidence on how well these products work in the real world.

Read Wall Street Journal article